MX2009008409A - Progesterona para la prevencion de nacimiento pretermino. - Google Patents

Progesterona para la prevencion de nacimiento pretermino.

Info

Publication number
MX2009008409A
MX2009008409A MX2009008409A MX2009008409A MX2009008409A MX 2009008409 A MX2009008409 A MX 2009008409A MX 2009008409 A MX2009008409 A MX 2009008409A MX 2009008409 A MX2009008409 A MX 2009008409A MX 2009008409 A MX2009008409 A MX 2009008409A
Authority
MX
Mexico
Prior art keywords
progesterone
treatment
preterm birth
prevention
spontaneous preterm
Prior art date
Application number
MX2009008409A
Other languages
English (en)
Inventor
George Creasy
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008409(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MX2009008409A publication Critical patent/MX2009008409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar o prevenir nacimiento pretérmino espontáneo en mujeres embarazadas y que mejora la morbilidad y mortalidad neonatal. El método incluye administrar a una mujer embarazada en necesidad del mismo una cantidad efectiva de una progesterona suficiente para prolongar la gestación al reducir al mínimo el acortamiento o borramiento de su cérvix. El tratamiento y profilaxis con progesterona en mujeres embarazadas que tienen síntomas de cérvix corta se ha mostrado clínicamente que incrementa la salud neonatal.
MX2009008409A 2007-02-06 2008-02-05 Progesterona para la prevencion de nacimiento pretermino. MX2009008409A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88848007P 2007-02-06 2007-02-06
US97366707P 2007-09-19 2007-09-19
PCT/GB2008/000397 WO2008096122A2 (en) 2007-02-06 2008-02-05 Progesterone for the prevention of preterm birth

Publications (1)

Publication Number Publication Date
MX2009008409A true MX2009008409A (es) 2009-09-16

Family

ID=39301249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008409A MX2009008409A (es) 2007-02-06 2008-02-05 Progesterona para la prevencion de nacimiento pretermino.

Country Status (24)

Country Link
US (2) US8828981B2 (es)
EP (1) EP2117554B1 (es)
JP (2) JP5580601B2 (es)
KR (1) KR101546101B1 (es)
AR (1) AR065179A1 (es)
AU (1) AU2008212724A1 (es)
BR (1) BRPI0807203A2 (es)
CA (1) CA2677354C (es)
CL (1) CL2008000375A1 (es)
CO (1) CO6220941A2 (es)
CR (1) CR10985A (es)
ES (1) ES2596803T3 (es)
GE (1) GEP20135727B (es)
HK (1) HK1136975A1 (es)
IL (1) IL200272A (es)
MA (1) MA31200B1 (es)
ME (1) ME00930B (es)
MX (1) MX2009008409A (es)
MY (1) MY184866A (es)
NZ (1) NZ579114A (es)
PE (1) PE20081738A1 (es)
RU (1) RU2524617C2 (es)
TW (1) TWI471135B (es)
WO (1) WO2008096122A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1535068E (pt) 2002-08-13 2010-07-01 N Dia Inc DISPOSITIVOS E MéTODOS PARA DETECTAR FLUIDO AMNIËTICO EM SECREÎES VAGINAIS
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
PL2249757T3 (pl) * 2008-02-04 2017-12-29 Ferring B.V. Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania
EP2334300B1 (en) 2008-09-24 2016-02-17 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Composition and method for treatment of preterm labor
GB0905964D0 (en) * 2009-04-06 2009-05-20 King S College London Marker
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
CA2789238C (en) * 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
WO2012058463A2 (en) * 2010-10-27 2012-05-03 Dignity Health Trimegestone (tmg) for treatment of preterm birth
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
DE102012009057A1 (de) * 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotationspessar mit zusätzlicher Wirkstoffkomponente
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140234987A1 (en) * 2013-01-02 2014-08-21 N-Dia, Inc. Methods for predicting time-to-delivery in pregnant women
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
BR112014030232A2 (pt) * 2014-06-28 2017-06-27 Laboratorios Andromaco S A cerclagem de pessário que contenham progesterona de longa, sustentada e contínua liberação útil para prevenção de parto prematuro
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
KR101726488B1 (ko) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
EP3310359A4 (en) * 2015-06-22 2019-04-03 Lipocine Inc. ORAL COMPOSITIONS CONTAINING 17-HYDROXYPROGESTERONE ESTER AND METHODS RELATING THERETO
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
US11029318B2 (en) * 2015-08-28 2021-06-08 Kypha, Inc. Methods for predicting and treating patients with increased risk of adverse pregnancy outcome
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3458070A4 (en) * 2016-05-16 2020-01-08 Amag Pharmaceuticals, Inc. PROLONGED RELEASE POLYMER COMPOSITIONS BASED ON HYDROXYPROGESTERONE CAPROATE AND METHODS OF USE THEREOF
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
JP2018140172A (ja) * 2017-02-28 2018-09-13 株式会社Ｎｔｔドコモ データ収集装置及びデータ収集方法
US11207509B2 (en) 2017-06-15 2021-12-28 Wiesman Holdings, LLC Method and device for delivery of a solution into a body orifice
RU2657772C1 (ru) * 2017-07-06 2018-06-15 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области Способ профилактики гестационных осложнений у беременных с эпилепсией
US20190038637A1 (en) * 2017-08-05 2019-02-07 Eric Marchewitz Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
EP3704270A1 (en) * 2017-10-30 2020-09-09 Carmentix Pte. Ltd. Biomarkers of preterm birth
RU2692932C2 (ru) * 2017-11-07 2019-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) БИОКАТАЛИЗАТОР ДЛЯ ПОЛУЧЕНИЯ 11α-АЦЕТОКСИПРОГЕСТЕРОНА
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
JP7301326B2 (ja) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 新生児期～小児期発症の脳小血管病又はその保因者の検出方法
KR102157438B1 (ko) * 2019-04-16 2020-09-21 고려대학교 산학협력단 조산 진단 방법 및 키트
CA3152099A1 (en) * 2019-09-23 2021-04-01 Liang Liang Methods of treatments to prolong gestation and complications of menstruation or gestation
US11439588B2 (en) 2019-10-12 2022-09-13 National Research Institute For Family Planning Vaginal sustained-release drug delivery system for luteal support, method for preparation and use thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR102482468B1 (ko) * 2020-08-11 2022-12-28 연세대학교 산학협력단 조산에 대한 정보 제공 방법 및 이를 적용한 디바이스
US20220072008A1 (en) * 2020-09-08 2022-03-10 Cedars-Sinai Medical Center Method of using progesterone receptor agonists for the treatment of covid-19
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
DE4229820C2 (de) 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
US5830848A (en) 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US5948762A (en) 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
RU2199346C2 (ru) 1995-03-14 2003-02-27 Шеринг Аг Применение доноров оксида азота или ингибиторов оксида азота для регулирования раскрытия и растяжения шейки матки
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6040340A (en) 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US5941888A (en) 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
IL127129A (en) 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
PE20010640A1 (es) 1999-06-21 2001-06-06 Columbia Lab Bermuda Ltd Uso de estrogeno exogeno o una sustancia que ocasione la liberacion del estrogeno para la programacion de la ovulacion
US6375970B1 (en) 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
AU2002313517B2 (en) 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
US20040266025A1 (en) 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
BRPI0516247A (pt) 2004-10-07 2008-08-26 Duramed Pharmaceuticals Inc métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente
EA015155B1 (ru) * 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Also Published As

Publication number Publication date
US7884093B2 (en) 2011-02-08
TW200902030A (en) 2009-01-16
RU2009133315A (ru) 2011-03-20
US20080188829A1 (en) 2008-08-07
WO2008096122A3 (en) 2009-02-26
CA2677354A1 (en) 2008-08-14
JP2010518058A (ja) 2010-05-27
CL2008000375A1 (es) 2008-05-30
MY184866A (en) 2021-04-28
KR20090123875A (ko) 2009-12-02
IL200272A (en) 2014-02-27
ES2596803T3 (es) 2017-01-12
US8828981B2 (en) 2014-09-09
NZ579114A (en) 2012-07-27
JP2014058529A (ja) 2014-04-03
HK1136975A1 (zh) 2010-07-16
CO6220941A2 (es) 2010-11-19
TWI471135B (zh) 2015-02-01
JP5580601B2 (ja) 2014-08-27
GEP20135727B (en) 2013-01-25
AU2008212724A1 (en) 2008-08-14
IL200272A0 (en) 2010-04-29
MA31200B1 (fr) 2010-02-01
CR10985A (es) 2009-10-23
EP2117554A2 (en) 2009-11-18
AR065179A1 (es) 2009-05-20
BRPI0807203A2 (pt) 2014-07-22
ME00930B (me) 2012-03-20
KR101546101B1 (ko) 2015-08-20
US20090264395A1 (en) 2009-10-22
RU2524617C2 (ru) 2014-07-27
WO2008096122A2 (en) 2008-08-14
EP2117554B1 (en) 2016-07-13
CA2677354C (en) 2015-07-07
PE20081738A1 (es) 2008-11-20

Similar Documents

Publication Publication Date Title
MY184866A (en) Progesterone for the treatment or prevention of spontaneous preterm birth
Herrell Nausea and vomiting of pregnancy
American College of Obstetricians and Gynecologists ACOG Committee opinion no. 549: obesity in pregnancy
Sultana et al. Efficacy of hijamat bila shurt (dry cupping) on intensity of pain in dysmenorrhoea-a preliminary study
American College of Obstetricians and Gynecologists ACOG Committee opinion no. 550: maternal-fetal surgery for myelomeningocele
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
Behmanesh et al. The effect of heat therapy on labor pain severity and delivery outcome in parturient women
PH12014501611A1 (en) Use of specific carbohydrate systems during pregnancy for effecting the offspring
American College of Obstetricians and Gynecologists ACOG Committee Opinion No. 427: misoprostol for postabortion care
MY172530A (en) Method for treating gynecological diseases
UA101474C2 (ru) Применение прогестерона для производства лекарственного средства
Jeon et al. A case of assisted reproductive therapy-induced erythema nodosum
MX2015012996A (es) Uso de sistemas de carbohidrato especificos durante el embarazo, para prevenir la acumulacion de grasa en mujeres embarazadas.
Hangekar et al. Our experience of nifedipine as a tocolytic agent in preterm labor (24 weeks to 36 weeks 6 days)
Yun et al. Research Progress of Chinese Medicine in the Treatment of Recurrent Miscarriage of Unknown Origin
Sheet Smoking and Infertility
Kripke Use of beta agonists in preterm labor
Alkareem et al. Comparison of Different Medical Treatment of Missed Abortion
Ayati Nausea: case report
Maurya et al. Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online)
MD335Y (en) Method for preparing the neck of uterus for induction of delivery in pregnants with prolonged pregnancy
Shao-Wei et al. Role of Cervical Cerclage and Vaginal Progesterone in the Treatment of Cervical Incompetence with/without Preterm Birth History
Aponte Low-dose oral contraceptives may be linked to painful orgasm
Ma et al. Epidemiological analysis of infertility in China
TH131029A (th) โพรเจสเทอโรนสำหรับการรักษา หรือการป้องกันการเกิดก่อนกำหนดที่เกิดขึ้นเอง